The interim 3-year OS rates were 71.2% with OST-HER2 vs 45.8% in historical controls in a phase 2b trial of fully resected, pulmonary metastatic osteosarcoma.
|Slideshows|December 14, 2016
Top Sarcoma News in 2016
Author(s)Cancer Network Editors
In this slide show we highlight some of the top news on sarcoma in 2016, including the first frontline FDA approval in 40 years, and studies on imaging in Ewing sarcoma, maintenance chemotherapy in osteosarcoma, and more.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
3
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
4
Secondary T-Cell Malignancies: Identifying and Counseling After CAR T-Cell Therapy
5